Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 955 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more
Conditions
Obesity, Weight Loss
Interventions
Rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 42 more
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-210, Gemcitabine, MMC
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more
Conditions
Crohn Disease
Interventions
TAK-018, TAK-018 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation
Other · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1249
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 764 more
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Hinsdale, Illinois • Urbana, Illinois • Boston, Massachusetts + 26 more
Conditions
Breast Cancer
Interventions
docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
62
States / cities
Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
488
States / cities
Mobile, Alabama • Anchorage, Alaska • Burbank, California + 295 more
Conditions
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more
Conditions
Asthma
Interventions
PARTICS using QVAR
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 14 more
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
144
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more
Conditions
Thoracoabdominal Aneurysm
Interventions
GORE Excluder Thoracoabdominal Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
19 Years and older
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions
LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Conditions
Ovarian Neoplasms
Interventions
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
234
States / cities
Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo matching BI 690517, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
8,371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
15
States / cities
Duarte, California • Irvine, California • San Francisco, California + 11 more
Conditions
Iliac Artery Stenosis
Interventions
Epic™ Nitinol Stent System, Anti-platelet therapy, Anti-coagulation therapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • Brandon, Florida • Fort Lauderdale, Florida + 24 more
Conditions
COVID-19
Interventions
Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
127
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more
Conditions
HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1259
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
Active, not recruiting Not applicable Interventional

CHAMPION-AF Clinical Trial

NCT04394546
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Scottsdale, Arizona • Duarte, California • Lancaster, California + 37 more
Conditions
Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Comprehensive Geriatric Assessment, Questionnaire Administration
Other
Lead sponsor
NRG Oncology
Other
Eligibility
70 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
392
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 282 more